Compare Stocks: EIKN, SNDX, STOK, and IMCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$7.47 -0.4%	$9.62	$7.01 ▼ $17.40	$404.61M	N/A	720,623 shs	288,680 shs
IMCR Immunocore	$29.39 +1.0%	$33.56	$27.56 ▼ $40.71	$1.51B	0.81	438,706 shs	452,840 shs
SNDX Syndax Pharmaceuticals	$16.99 +0.5%	$19.03	$12.99 ▼ $25.59	$1.51B	0.42	1.90 million shs	1.46 million shs
STOK Stoke Therapeutics	$24.74 +3.3%	$29.43	$20.32 ▼ $40.22	$1.60B	1.26	1.01 million shs	918,952 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	0.00%	+1.91%	-18.89%	-29.40%	+746,999,900.00%
IMCR Immunocore	0.00%	-1.08%	-12.48%	-8.01%	-13.53%
SNDX Syndax Pharmaceuticals	0.00%	-3.47%	-9.72%	-28.04%	+2.97%
STOK Stoke Therapeutics	0.00%	-3.43%	-15.68%	-21.16%	-18.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$7.47 -0.4%	$9.62	$7.01 ▼ $17.40	$404.61M	N/A	720,623 shs	288,680 shs
IMCR Immunocore	$29.39 +1.0%	$33.56	$27.56 ▼ $40.71	$1.51B	0.81	438,706 shs	452,840 shs
SNDX Syndax Pharmaceuticals	$16.99 +0.5%	$19.03	$12.99 ▼ $25.59	$1.51B	0.42	1.90 million shs	1.46 million shs
STOK Stoke Therapeutics	$24.74 +3.3%	$29.43	$20.32 ▼ $40.22	$1.60B	1.26	1.01 million shs	918,952 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	0.00%	+1.91%	-18.89%	-29.40%	+746,999,900.00%
IMCR Immunocore	0.00%	-1.08%	-12.48%	-8.01%	-13.53%
SNDX Syndax Pharmaceuticals	0.00%	-3.47%	-9.72%	-28.04%	+2.97%
STOK Stoke Therapeutics	0.00%	-3.43%	-15.68%	-21.16%	-18.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	234.67% Upside
IMCR Immunocore	2.58	Moderate Buy	$56.38	91.82% Upside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$41.80	146.03% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	78.86% Upside

Current Analyst Ratings Breakdown

Latest EIKN, SNDX, STOK, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/1/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/29/2026	SNDX Syndax Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/16/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/10/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	$400.02M	3.78	N/A	N/A	$7.52 per share	3.91
SNDX Syndax Pharmaceuticals	$172.35M	8.74	N/A	N/A	$0.74 per share	22.96
STOK Stoke Therapeutics	$184.42M	8.66	N/A	N/A	$6.17 per share	4.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	-$35.51M	-$0.37	N/A	117.56	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest EIKN, SNDX, STOK, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	IMCR Immunocore	-$0.1204	N/A	N/A	N/A	$152.86 million	N/A
11/3/2026	Q3 2026	STOK Stoke Therapeutics	-$0.9291	N/A	N/A	N/A	$8.21 million	N/A
11/2/2026	Q3 2026	SNDX Syndax Pharmaceuticals	-$0.4793	N/A	N/A	N/A	$82.41 million	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EIKN Eikon Therapeutics	N/A	9.89	9.89
IMCR Immunocore	0.94	4.47	4.44
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EIKN Eikon Therapeutics	N/A
IMCR Immunocore	84.50%
SNDX Syndax Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
EIKN Eikon Therapeutics	N/A
IMCR Immunocore	10.10%
SNDX Syndax Pharmaceuticals	4.80%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
SNDX Syndax Pharmaceuticals	298	88.61 million	84.36 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

EIKN, SNDX, STOK, and IMCR Headlines

Recent News About These Companies

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

October 10 at 1:07 AM | finance.yahoo.com

Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting

October 6, 2026 | marketscreener.comM

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...

October 6, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?

October 6, 2026 | marketbeat.com

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 6, 2026 | businesswire.com

Stoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For Zorevunersen

October 5, 2026 | marketscreener.comM

Stoke Therapeutics stock heads into November 3 results below key averages

October 5, 2026 | ad-hoc-news.deA

Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...

October 5, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock

October 3, 2026 | insidertrades.com

Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

October 2, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock

October 2, 2026 | marketbeat.com

Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 27, 2026 | marketbeat.com

Stoke Therapeutics, Inc. Announces Board Changes

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

September 23, 2026 | businesswire.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 9% - What's Next?

September 23, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | marketbeat.com

Stoke Therapeutics stock holds gains after recent data update

September 19, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SNDX, STOK, and IMCR Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

$7.47 -0.03 (-0.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.47 0.00 (0.00%)

As of 10/9/2026 07:47 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Immunocore NASDAQ:IMCR

$29.39 +0.30 (+1.03%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$29.40 +0.00 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Syndax Pharmaceuticals NASDAQ:SNDX

$16.99 +0.09 (+0.53%)

As of 10/9/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$24.74 +0.79 (+3.30%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$24.74 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SNDX, STOK, and IMCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SNDX, STOK, and IMCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SNDX, STOK, and IMCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SNDX, STOK, and IMCR Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Immunocore NASDAQ:IMCR

Syndax Pharmaceuticals NASDAQ:SNDX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SNDX, STOK, and IMCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SNDX, STOK, and IMCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SNDX, STOK, and IMCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SNDX, STOK, and IMCR Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Immunocore NASDAQ:IMCR

Syndax Pharmaceuticals NASDAQ:SNDX

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools